| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b48a2a85c81988c0c8db9230711e0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4211cd4f81bcc6f359fd0a5d58c1e0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c41f60b61548cc83da263542e75e7745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eeb1b6778632521d8bdf48e784682ece
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c928571793c3adcd87f48a073ad0c113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10cf7e22ebb316712838641e81f86584
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_219eb9b1bf49f99926f5809b3c2df0af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96ea543c844c16718878a2aed9b9ef26 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2010-05-21^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-05-06^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_461c4c050fa17beb22dc4e3168fd03de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed9b0755d169e8ed6276f205a1371374
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa4bd8cafd16d3341e3f0b6dedd574f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db26bc659b76c147b6f7487e6471709d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30cf9fb10e9c57252c992db1a4eec500
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5dbc9c4972b73850e2ab727b3b78e6fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_410d49048813266ba403b4450045309d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bccd0b65f03ae16fd05329138559422e |
| publicationDate |
2014-05-06^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8716234-B2 |
| titleOfInvention |
Cytotoxins comprising modified bouganin toxin for the treatment of cancer |
| abstract |
The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9601205-B2 |
| priorityDate |
2004-03-19^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |